RalA signaling pathway as a therapeutic target in hepatocellular carcinoma (HCC). Issue 5 (13th April 2014)

• Record Type: Journal Article
• Authors: Ezzeldin, Mohamad; Borrego-Diaz, Emma; Taha, Mohammad; Esfandyari, Tuba; Wise, Amanda L.; Peng, Warner; Rouyanian, Alex; Asvadi Kermani, Atabak; Soleimani, Mina; Patrad, Elham; Lialyte, Kristina; Wang, Kun; Williamson, Stephen; Abdulkarim, Bashar; Olyaee, Mojtaba; Farassati, Faris
• Is Part Of: Molecular oncology. Volume 8:Issue 5(2014:Jul.)
• Page Start: 1043
• Page End: 1053
• Publication Date: 2014-04-13
• Subjects: Ral -- HCC -- Treatment -- Cancer stem cells -- RalBP1 -- Signaling -- Aurora kinase -- FXR; Cancer -- Molecular aspects -- Periodicals; 616.994005
• DOI: 10.1016/j.molonc.2014.03.020
• Languages: English
• ISSNs: 1574-7891

Abstract

Abstract : Ral (Ras like) leads an important proto‐oncogenic signaling pathway down‐stream of Ras. In this work, RalA was found to be significantly overactivated in hepatocellular carcinoma (HCC) cells and tissues as compared to non‐malignant samples. Other elements of RalA pathway such as RalBP1 and RalGDS were also expressed at higher levels in malignant samples. Inhibition of RalA by gene‐specific silencing caused a robust decrease in the viability and invasiveness of HCC cells. Additionally, the use of geranyl–geranyl transferase inhibitor (GGTI, an inhibitor of Ral activation) and Aurora kinase inhibitor II resulted in a significant decrease in the proliferation of HCC cells. Furthermore, RalA activation was found to be at a higher level of activation in HCC stem cells that express CD133. Transgenic mouse model for HCC (FXR‐Knockout) also revealed an elevated level of RalA‐GTP in the liver tumors as compared to background animals. Finally, subcutaneous mouse model for HCC confirmed effectiveness of inhibition of aurora kinase/RalA pathway in reducing the tumorigenesis of HCC cells in vivo. In conclusion, RalA overactivation is an important determinant of malignant phenotype in differentiated and stem cells of HCC and can be considered as a target for therapeutic intervention. Highlights: RalA leads an important proto‐oncogenic signaling pathway down‐stream of Ras. RalA is significantly overactivated in HCC cells and tissue samples. Silencing RalA decreases the viability and invasiveness of HCC cells. RalA activation was found to be higher in CD133 + enriched HCC cells. Inhibition of aurora kinase/RalA prevents growth of HCC human cells in nude mice.